{"id":17213,"date":"2026-06-06T04:32:00","date_gmt":"2026-06-06T02:32:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=a632116085e50b404fee21c8b24d12d0"},"modified":"2026-06-06T04:32:00","modified_gmt":"2026-06-06T02:32:00","slug":"tidepool-showcases-new-real-world-clinical-data-and-landmark-womens-health-initiative-at-ada-2026","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=17213","title":{"rendered":"Tidepool Showcases New Real-World Clinical Data and Landmark Women\u2019s Health Initiative at ADA 2026"},"content":{"rendered":"<p>PALO ALTO, Calif.--(BUSINESS WIRE)--Tidepool, the nonprofit leader advancing innovation in diabetes technology, today unveiled new clinical insights and research initiatives in conjunction with the American Diabetes Association\u2019s (ADA) 86th Scientific Sessions. The company\u2019s presentation slate focuses on the immediate utility of real-world data and Tidepool\u2019s ongoing commitment to closing gaps in women\u2019s health research.<\/p><br\/><a href=\"https:\/\/mms.businesswire.com\/media\/20260605767760\/en\/773149\/5\/Tidepool_Logo_Light_Large_%281%29.jpg\"><img src=\"https:\/\/mms.businesswire.com\/media\/20260605767760\/en\/773149\/22\/Tidepool_Logo_Light_Large_%281%29.jpg\" \/><\/a><br\/><a href=\"https:\/\/mms.businesswire.com\/media\/20260605767760\/en\/773149\/5\/Tidepool_Logo_Light_Large_%281%29.jpg\"><img src=\"https:\/\/mms.businesswire.com\/media\/20260605767760\/en\/773149\/21\/Tidepool_Logo_Light_Large_%281%29.jpg\" \/><\/a><p>\nToday\u2019s insights demonstrate sustained progress in the adoption of accessible, data-driven diabetes management, supporting both persons with diabetes and the clinicians who care for them.<\/p><p>\n<b>Optimizing Resource-Limited Care: Helping Clinicians Prioritize Patient Engagement<\/b><\/p><p>\nTidepool\u2019s current ecosystem continues to yield critical insights for expanding remote, data-driven diabetes management in historically underserved communities.<\/p><p>\nIn a poster presentation at ADA<sup>1<\/sup>, Tidepool medical advisor Dr. Sushma Reddy shared results from a 24-week Diabetes Care Management Program (DCMP) used within a resource-limited healthcare setting supporting adults with uncontrolled type 2 diabetes. By leveraging continuous glucose monitoring (CGM) data streamlined through Tidepool\u2019s TIDE clinic dashboard and supported by a remote patient monitoring framework, the care team efficiently prioritized weekly outreach to patients requiring immediate support or education, achieving:<\/p><ul class=\"bwlistdisc\">\n<li>\nA 1.59% reduction in HbA1c<\/li>\n<li>\nA +13.4% increase in Time in Range<\/li>\n<\/ul><p>\n\u201cWe\u2019ve shown that we can change the trajectory of care in patients with diabetes, even in some of our most challenged safety-net environments,\u201d said Dr. Reddy. \u201cBy engaging these patients through CGM and providing tools that allow clinicians to quickly identify who needs immediate follow-up, providers can drive meaningful improvements without exhausting limited resources.\u201d<\/p><p>\n<b>Driving Equity: A Landmark Initiative in Women\u2019s Health<\/b><\/p><p>\nBeyond clinical data, Tidepool is driving a critical conversation around gender equity in diabetes research. Maya Friedman, Tidepool\u2019s Director of Product Design and User Experience, took the stage at DiabetesMine\u2019s DData ExChange on June 5 to discuss the company\u2019s vision for improved women\u2019s health for patients with diabetes.<\/p><p>\nFriedman recapped initial results from menstrual cycle research conducted in partnership with Diabetes Center Berne and outlined Tidepool\u2019s vision for a landmark initiative launched last fall at the Milken Institute Women\u2019s Health Network event. In collaboration with \u014cURA and other health leaders, the initiative aims to build the largest available opt-in, anonymized dataset of biometric and diabetes device data.<\/p><p>\n\"For too long, the unique lifecycle stages of women have been underrepresented in diabetes care,\" said Friedman. \"By capturing this multi-signal dataset, we can provide the objective evidence needed to design targeted therapies and technologies for women navigating everything from menstrual cycles to menopause.\"<\/p><p>\n<b>Streamlining Meal Management: Expanding Evidence for AID Algorithm Enhancements<\/b><\/p><p>\nMeal logging continues to be a heavy mental burden for people living with type 1 diabetes. A collaborative study presented by Stanford University, Replica Health, and Tidepool<sup>2<\/sup> evaluated how personalized meal records could improve glycemic control while reducing manual steps for automated insulin delivery (AID) users.<\/p><p>\nEvaluating a 40-day period of meal-logging behavior from a mix of participants who self-identified as using accurate, mixed, and approximate meal-logging strategies, the data revealed that repeated meals are associated with better postprandial glycemic outcomes, even when carb-counting is approximate or inconsistent.<\/p><p>\n\u201cOur roadmap for Tidepool Loop is focused on lifting the burdens for people living with diabetes, and meal logging is one of the heaviest,\u201d said Kelly Watson, Chief Product Officer. \u201cThis study demonstrates another opportunity to move beyond the demand for constant precision. By harnessing an individual\u2019s real-world data, we have a clear opportunity to advance AID systems and deliver deeply personalized experiences.\u201d<\/p><p>\n<b>A Vision for Connected Care<\/b><\/p><p>\nWrapping up the company's update, Tidepool CEO and Co-founder Brandon Arbiter emphasized the broader implications of Tidepool's presence at the event.<\/p><p>\n\u201cAt Tidepool, we are looking for ways to make the biggest impact for our users and the broader diabetes community,\u201d added Arbiter. \u201cThese discussions at the American Diabetes Association bring together innovators, clinicians, and those of us living with diabetes to advocate for new developments that transform how we interact with our health data every day. Our focus remains on proving how data can be harnessed to create a more personalized, equitable ecosystem for everyone.\u201d<\/p><p>\n<b>About Tidepool<\/b><\/p><p>\nTidepool is a recognized innovator in diabetes software on a mission to make diabetes data more accessible, actionable, and meaningful for people with diabetes, their care teams, and researchers. Founded in 2013, Tidepool hosts a suite of software tools for people with diabetes and the clinics that serve them, including Tidepool+, Tidepool Mobile, Tidepool Uploader, and the FDA-cleared Tidepool Loop. Through strategic industry partnerships, Tidepool Loop is commercially available via partner-developed adaptations, such as the twiist\u2122 AID System powered by Tidepool, now available in the iOS App Store. Built with enterprise-grade security, the Tidepool platform is HIPAA-compliant and SOC 2 Type II-compliant. Tidepool is a registered 501(c)3 nonprofit organization. Learn more at <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Ftidepool.org&amp;esheet=54548572&amp;newsitemid=20260605767760&amp;lan=en-US&amp;anchor=tidepool.org&amp;index=1&amp;md5=e6c687ccf5a7b767cccaeb737b4bc818\" rel=\"nofollow\" shape=\"rect\">tidepool.org<\/a>. Follow us on <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.linkedin.com%2Fcompany%2Ftidepoolorg&amp;esheet=54548572&amp;newsitemid=20260605767760&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=2&amp;md5=ab85f90a9d8aef9d0a5ce1459a2fd29e\" rel=\"nofollow\" shape=\"rect\">LinkedIn<\/a>.<\/p><table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl\">\n<tr>\n<td class=\"bwpadl0\" colspan=\"3\" rowspan=\"1\">____________________<\/td>\n<\/tr>\n<tr>\n<td class=\"bwalignl bwvertalignt\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignl bwcellpmargin\">\n<sup>1<\/sup><\/p><\/td><td colspan=\"1\" rowspan=\"1\"\/>\n<td class=\"bwvertalignt bwpadl0\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nReddy S, Henry K, Heidenreich M, Lucas SA, Reddy S. Using CGM and RPM in Safety Net Clinics: Feasibility and Impact. Poster presented at the American Diabetes Association 86th Scientific Sessions; 2026.<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwalignl bwvertalignt\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignl bwcellpmargin\">\n<sup>2<\/sup><\/p><\/td><td colspan=\"1\" rowspan=\"1\"\/>\n<td class=\"bwvertalignt bwpadl0\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nRoyston SF, Wolff MK, Khan-Gallo S, Friedman M, Brydges C, Lal R. Meal Logging Behavior and Glycemic Control in Users of the Loop Automated Insulin Delivery System. Poster presented at: American Diabetes Association 86th Scientific Sessions; 2026.<\/p><\/td><\/tr>\n<\/table><p>\n\u00a0<\/p><br\/> <b>Contacts<\/b> <br\/><p>\nMedia Contacts:\n<br\/>Allison Orenstein\n<br\/><a  href=\"mailto:media@tidepool.org\" rel=\"nofollow\" shape=\"rect\">media@tidepool.org<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>PALO ALTO, Calif.&#8211;(BUSINESS WIRE)&#8211;Tidepool, the nonprofit leader advancing innovation in diabetes technology, today unveiled new clinical insights and research initiatives in conjunction with the American Diabetes Association\u2019s (ADA) 86th Scientific &#8230;<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-17213","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/17213","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=17213"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/17213\/revisions"}],"predecessor-version":[{"id":17214,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/17213\/revisions\/17214"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=17213"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=17213"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=17213"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}